ORIGINAL ARTICLE

A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer

MA Trujillo1, MJ Oneal2, S McDonough1, R Qin3 and JC Morris1

The sodium-iodide symporter (NIS) directs the uptake and concentration of iodide in thyroid cells. We have extended the use of NIS-mediated radioiodine therapy to prostate cancer. We have developed a prostate tumor specific conditionally replicating adenovirus that expresses hNIS (Ad5PB_RSV-NIS). For radiovirotherapy to be effective in humans, the radioiodine dose administered in the pre-clinical animal model should scale to the range of acceptable doses in humans. We performed 131I dose-response experiments aiming to determine the dose required in mice to achieve efficient radiovirotherapy. Efficacy was determined by measuring tumor growth and survival times. We observed that individual tumors display disparate growth rates that preclude averaging within a treatment modality indicating heterogeneity of growth rate. We further show that a statistic and stochastic approach must be used when comparing the effect of an anti-cancer therapy on a cohort of tumors. Radiovirotherapy improves therapeutic value over virotherapy alone by slowing the rate of tumor growth in a more substantial manner leading to an increase in survival time. We also show that the radioiodine doses needed to achieve this increase scaled well within the current doses used for treatment of thyroid cancer in humans.

Cancer Gene Therapy (2012) 19, 839–844; doi:10.1038/cgt.2012.68; published online 5 October 2012

Keywords: adenovirus; allometry; probasin; prostate cancer; radiovirotherapy; sodium-iodide symporter

INTRODUCTION

Prostate cancer is the second leading cause of cancer death in men.1 To date, no uniformly curative therapy for metastatic prostate cancer has been developed. In some malignancies, for which existing treatment regimens are not completely effective, suicide gene therapy and virotherapy strategies targeting the tumor-associated genetic alterations represent rational directions for the development of novel therapeutics.2–4

The sodium-iodide symporter (NIS) is a transmembrane glycoprotein that mediates uptake of iodide into cells, especially thyroid follicular cells.5,6 The presence of NIS on the basolateral membrane of thyroid cells has been exploited for many years for diagnostic imaging purposes as well as for ablative therapy of differentiated thyroid cancer using radioactive iodide (131I). This non-invasive therapy has proven to be a safe and effective treatment for thyroid cancer, even in advanced, metastatic disease.7,8 In order to extend the use of NIS-mediated radioiodine therapy to other types of cancer, we have successfully transferred and expressed the NIS gene in prostate, colon and breast cancer cells, both in vivo and in vitro, using adenoviral vectors. Our experience with adenovirus-mediated NIS transfer and radioiodine therapy was confirmed in large animal model and has culminated in the opening of a phase I trial for prostate cancer that is currently accruing patients.9–13

Two major problems need to be circumvented to translate gene therapy into the clinical setting. First, the limited ability to efficiently transduce tumors with effective levels of therapeutic transgenes has been identified as the fundamental barrier to effective cancer gene therapy.14,15 A second conclusion that can be drawn from recent virotherapy clinical trials is that multimodal therapy, combining virotherapy (that is, viral-mediated tumor cytolysis) with chemo- or radiotherapy may be necessary for more complete tumor eradication as opposed to mono-therapy using virotherapy alone.16

Our approach towards the current problems associated with virotherapy/gene therapy has been the development of tumor specific, conditionally replicating adenoviral vectors that also harbor the NIS gene.17 In this conditionally replicating adenovirus (CRAd) Ad5PB_RSV-NIS, the transcriptional control of the E1A gene is governed by a composite probasin promoter to reduce extratumoral toxicity and induce tumor selective replication and tumor lysis. NIS expression allows for non-invasive imaging as well as radioiodine-mediated therapy. This combination of virus-mediated oncolysis and NIS-mediated radioiodine therapy has been termed ‘Radiovirotherapy’.18 However, for radiovirotherapy to be effective in humans, the radioiodine dose administered to the pre-clinical animal must scale to the range of acceptable doses in humans. Despite the fact that the principles of allometric scaling were put forward as far as back as 1936, they are still poorly understood.19,20 These principles are based upon the observation that the overall metabolic rate decreases as animals get larger. Thus, calculating equivalent doses from smaller to larger animals (or humans) using linear extrapolation based solely on weight leads to overdosing that can lead to unreasonable doses and even disastrous consequences.21–23 Thus, allometric scaling of human acceptable range of doses should be tested on pre-clinical animals to ascertain their efficacy.

1Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN, USA; 2Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA and 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Correspondence: Dr JC Morris, Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
E-mail: morris.john@mayo.edu
Received 2 August 2012; revised 30 August 2012; accepted 31 August 2012; published online 5 October 2012
An effort to characterize the objective response to anti-cancer treatments culminated with the adoption of the RECIST (response evaluation criteria in solid tumors) guidelines by the World Health Organization. Tumor growth has been one of the metrics used to determine the effect of anti-cancer treatments and a number of methods of modeling tumor growth have been developed. In particular for radiovirotherapy, these tumor growth models are based on analytical functions of population dynamics and assume the existence of equilibrium points related to the outcome of the therapy. However, these models also assume that, within a cohort, tumor growth is homogenous. Experience shows that this is not the case, since, for most tumor growth curves found in the literature, large standard deviations have been observed.

Using the Ad5PB_RSV-NIS CRAd, we report here a $^{131}$I dose-response study with the aim to determine the dose required in mice to achieve efficient radiovirotherapy. Our findings show that these doses can be fully scaled to the doses used in humans for treatment of thyroid cancer.

**MATERIALS AND METHODS**

**CRAd construction**

The structure Ad5PB_RSV-NIS CRAd was described elsewhere.

**Cell culture**

The androgen-dependent (LnCaP) prostate cancer cell line was cultured as described.

**Animal experiments**

Experimental protocols were approved by and experiments were completed under the guidelines of the Mayo Foundation Institutional Animal Care and Use Committee. All animals were purchased from Harlan Laboratories (Indianapolis, IN, USA) and maintained in the Mayo Foundation animal barrier facilities.

**Subcutaneous tumor model**

Xenografts derived from the LnCaP cell line were established into the right flanks of 4- to 6-week-old athymic nude Foxn1nu mice (Harlan) by subcutaneous injection of $4 \times 10^5$ cells resuspended in 0.125 microliters media and 0.125 microliters of BD Matrigel basement membrane matrix (BD Biosciences, Bedford, MA, USA). Mice were maintained on a low iodine diet and T4 supplementation (5 mg/l) in their drinking water throughout the duration of the experiment to maximize radioisotope uptake in the tumor and minimize uptake by the thyroid. The mice were examined daily for tumor development.

**Efficacy studies**

All mice were subcutaneously engrafted with LnCaP as described above. Mice were divided into groups (average group size, $n = 10 \pm 3$) randomly at time 0. The average tumor size at time 0 was $125 \pm 30$ mm$^3$. One group of mice was used as control (C), a second group received a single intratumoral dose of Ad5PB_RSV-NIS at $10^{11}$ vp and 4 days later a single intraperitoneal dose of 0.5, 1 or 3 mCi $^{131}$I. Scaling from a 0.02-kg mouse to a 75-kg humans, these doses will be equivalent to 4.6 GBq (124 mCi), 9.2 GBq (248 mCi) and 27.5 GBq (744 mCi), respectively, using the body surface area (BSA) method. Tumor volume was measured twice weekly for a total of 21 days. Tumor growth curves were constructed (Figure 1) and analyzed following three models: Linear, Logistic and Gompertz and the best fit was determined (Table 1). In the linear model, all slopes were different from 0 except for mice treated with virus plus 3 mCi of $^{131}$I. Fitting the growth curves by the logistic model yielded the same result, in that only in mice treated with virus plus 3 mCi the model did not converge. We then used the more stringent Gompertz model. In this model, mice treated with virus plus 1 or 3 mCi of the $^{131}$I radioisotope could not be modeled. These results indicate that, despite the fact that tumor growth is slowed by virotherapy, tumors continue to grow. On the other hand, the fact that tumor growth could not be fitted by either a logistic or a Gompertz model in the radiovirotherapy cohorts when doses of 1 or 3 mCi of the $^{131}$I were administered indicates that radiovirotherapy induced a profound negative effect on tumor growth. This observation is in agreement with a previous report in which more sophisticated fitting equations that take into account the dynamic states between the combined effects of tumor growth, virus replication and radiation are needed.

**RESULTS**

Radioiodine dose-response; tumor growth

One key question about the feasibility of radiovirotherapy is whether the minimal effective radioiodine dose that is required for efficacy in animal models can be translated to humans. To answer this question, LnCaP xenografts were established in four groups of mice (average group size, $n = 10 \pm 3$). One group of mice was used as control (C), a second group received a single intratumoral dose of Ad5PB_RSV-NIS at $10^{11}$ vp (virotherapy V), and the following groups received a single intratumoral injection of Ad5PB_RSV-NIS at $10^{11}$ vp and 4 days later a single intraperitoneal dose of 0.5, 1 or 3 mCi $^{131}$I. The average group size is $n = 10 \pm 3$. NIS, sodium-iodide symporter.

![Figure 1. Tumor growth kinetics. Mice were subcutaneously engrafted with LnCaP, one group of mice was used as control (C), a second group received a unique intratumoral dose of Ad5PB_RSV-NIS at $10^{11}$ vp (virotherapy V), and the remaining groups received a unique intratumoral dose of Ad5PB_RSV-NIS at $10^{11}$ vp and 4 days later a single $^{131}$I intraperitoneal dose of 0.5, 1 or 3 mCi. The average group size is $n = 10 \pm 3$. NIS, sodium-iodide symporter.](image)

| Table 1. Tumor growth curves models |
|-------------------------------------|
| Linear (test: slope ≠ 0) | Logistic | Gompertz |
| Control | Fit | Fit | Fit |
| Virus | Fit | Fit | Fit |
| Virus + 0.5 mCi $^{131}$I | Fit | Fit | Does not fit |
| Virus + 1 mCi $^{131}$I | Does not fit | Does not fit | Does not fit |
| Virus + 3 mCi $^{131}$I | Does not fit | Does not fit | Does not fit |

The tumor growth curves were fitted according to a linear, a logistic, or a Gompertz model. $P$-values were estimated to validate the fitting model. $P < 0.05$ model does not fit, $P > 0.05$ model fits.
to fit tumor growth following radiovirotherapy. Taking together, our data indicate that a minimal dose of 1 mCi of therapeutic radioiodine is necessary for radiovirotherapy to improve on virotherapy alone.

Although modeling tumor growth using analytical functions yields useful information, the large standard errors reflect wide intragroup variations in tumor growth. In consequence, tumors cannot be averaged within a treatment modality because averaging presumes homogeneity of growth rate. This is demonstrated in Figure 2 where the growth of individual tumors within each experimental cohort is graphed. Tumors appear to group in classes with different growth rates even within a single treatment. Therefore, we employed a stochastic approach, rather than an analytical approach, to analyze the effect of virotherapy and radiovirotherapy on tumor outcome. First, the tumor growth curves of the control cohort were analyzed using the repeated measures test. The test showed that three distinct and statistically different groups emerge. The growth curves within each group were averaged to yield a representative curve for the group (Figure 3a). All three groups differed significantly from one another (P<0.05). This analysis confirms that the rate of tumor growth is heterogeneous with an order of growth rate CG1>CG2>CG3.

We then decided to compare all tumors individually regardless of the treatment received using repeated measures analysis. Since in our first analysis we found that a dose of 0.5 mCi of $^{131}$I did not yield any improvement over virus alone, we substituted this dose for a dose of 2 mCi (equivalent to 18.5 GBq (496 mCi) in a 75-kg human). Applying repeated measures analysis, all tumors can be sorted into four statistically significantly different groups according to their growth rate: F, MF, MS and S (Figure 3b). These four groups range from fast growing tumors (F) to tumors with an apparent zero growth rate (S) in the order F>MF>MS>S. The growth rate is independent of tumor size at time 0 since a Kruskal–Wallis one-way analysis of variance on ranks comparing all tumors according to the treatment they were submitted yielded no statistically significant difference ($H=6.844$ with 4 degrees of freedom ($P=0.144$)). Thus, the differences in tumor growth rates are intrinsic to each tumor, and not related to its volume at time 0. We then assigned each tumor to its growth rate class. The results in Table 2 indicate that treatment causes a shift towards higher numbers of the slower growing tumors. In untreated controls more than half the tumors fell into the fast growing class of tumors (7/12 in group F), while no tumor was scored in the zero growth class (0/12 in group S). The number of tumors in the F group declined abruptly in the virotherapy treatment (2/10 in group S). However, virotherapy alone did not result in shifting of tumors towards the zero growth class (0/10 in group S). On the other hand, treatment with $^{131}$I resulted in a significant shift from the fast growing tumors to the more slow growing tumors, including a larger proportion in the zero growth class. This trend was observed with radioiodine dose of 1 mCi and did not vary to a great extent as the radioiodine doses were increased.

Taken together, our data indicate that both virotherapy and radiovirotherapy induced an overall decrease in the growth rate of the tumors but the combination of radiotherapy and cytolytic virotherapy was superior to virotherapy alone, which was itself a moderate improvement over control. However, this effect was not
absolute and different tumors responded differently to the treatment.

Radioiodine dose-response; survival

Analysis of tumor growth could not be extended past day 21 because, by week 3, a significant number of control animals reached euthanization criteria thus rendering the statistical test meaningless. For a long-term study, we investigated how treatment with Ad5PB_RSV-NIS CRAd, with or without $^{131}$I radiotherapy, impinges on survival. The survival times of each group were graphed using Kaplan–Meier curves (Figure 4). The end point event was set at tumor burden $\geq 1000$ mm$^3$, while death before end point was considered as censoring. By week 8, all animals in the control group reached tumor sizes $\geq 1000$ mm$^3$ and, according our animal use committee guidelines, were euthanized. Virotherapy resulted in a net improvement in survival beyond that achieved with virotherapy alone. The survival times were subjected to a Cox proportional hazards survival regression model (Figure 4). The hazard ratio of virotherapy vs control was 0.342 ($P = 0.024$) while radiovirotherapy yielded hazard ratios ranging from 0.29 to as low as 0.15 and $P$-values that were between one and two order of magnitude lower than those of virotherapy alone. Again, treatment with 1 mCi $^{131}$I was sufficient to improve the treatment result, but escalating the dose up to 3 mCi did not significantly improve the efficacy (Figure 4). These results confirm that the combination of radiotherapy and cytolytic virotherapy was superior to virotherapy alone.

Correlation tumor growth to survival time

Because we followed the rate of tumor growth and survival time in individual mice, we can compare and correlate these two parameters. We scored the frequency of animal death at a particular time and compared that with the frequency of the growth classes of tumor. It can be clearly seen in Figure 5 that mice bearing fast growing tumors died within the first 5 weeks while mice bearing more slowing growing tumors reached the censoring size later in time. By week 13, of the 7 mice that were still alive, 6 bore tumors of type S and one of type MF. Of these, three were treated with virus plus 1 mCi $^{131}$I and four with 3 mCi. Thus, a strong correlation between the rate of tumor growth and the survival time was found thus validating the growth analysis. Moreover, this result also shows that only mice treated with radiovirotherapy have a better probability of survival. Finally, these

Figure 3. Repeated measures analysis. (a) The tumor growth of the individual tumors within the control cohort was analyzed using the repeated measures test. Three statistically significantly different groups of tumors, termed CG1, CG2 and CG3, were revealed in which each group differs by its rate of growth. (b) The same test was applied to all tumors regardless of the treatment. Here, four different groups of tumors, termed F, MF, MS and S were revealed in which each group differs by its rate of growth.

Figure 4. Survival analysis. Survival was plotted according to Kaplan–Meier and analyzed using the Cox proportional hazards survival regression.
that a dose of 1 mCi of $^{131}$I is sufficient to provoke a tumor response that is superior to that of virotherapy alone. Increasing the dose to 3 mCi did not result in a significant increase of efficacy when compared with lower doses.

**DISCUSSION**

We have reported the use of prostate targeted conditionally replicating adenoviruses expressing the NIS protein in in vivo mouse models of prostate cancer.\(^1\)\(^7\) We have shown in this report that a dose of 1 mCi of $^{131}$I is sufficient to provoke a tumor response that is superior to that of virotherapy alone. Hence, a steep dose response to $^{131}$I treatment in which a jump from no effect at 0.5 mCi to full effect at 1 mCi was observed. Moreover, a plateau was reached at 1 mCi since increasing the dose to 2 and 3 mCi did not produce any additional benefit. This observation suggests that a saturation in the NIS ability to pump and concentrate circulating radiiodine into the tumor is reached at a dose of 1 mCi.

The idea of the use of the NIS gene as a therapeutic gene for malignant diseases arose from the utility and efficacy of $^{131}$I therapy in thyroid cancer patients.\(^3\)\(^7\) One of the central questions in the translation of this NIS-based methodology into the clinic is whether the doses of radiiodine used in the animal models are scalable to humans. Dose conversions have by some authors been based on linear extrapolation based solely on weight. Based on their calculations, Siddiqui et al.\(^2\)\(^7\) found that the Na$^{131}$I dose needed for NIS-mediated imaging in dogs was 10 times larger than that to be administrated to humans, when in fact the human equivalent dose if calculated based on BSA and their experimental observations is only two times larger. Two major methods have been used to plan radiiodine dosing in humans: empiric fixed doses, and dosimetrically determined doses. While the most common empirical $^{131}$I doses for advanced thyroid cancer range from 150 to 300 mCi, dosimetrically determined doses can be considerably higher, ranging from 300 to 600 mCi.\(^2\)\(^8\) The Food and Drug Administration of the United States formulated a table of dose conversion factors that allow for allometric adaptation from pre-clinical animals to humans based on BSA.\(^2\)\(^9\) This table is formulated for 60 kg humans. After adjusting the general BSA formula for a more realistic 75 kg human,\(^2\)\(^9\) doses between 1 and 2 mCi of $^{131}$I in mice scale to between 248 mCi, and 496 mCi in humans. It has been stressed that using BSA for dose calculation is not fully accurate leading to ~10% of patients being overdosed and 30% underdosed. This observation led to the recommendation that BSA should be used to estimate a dose range rather than determining an absolute dose.\(^3\)\(^0\) Despite these general caveats, the $^{131}$I doses that we have used in the current studies in mice fell well within comparable ranges used in humans for treatment of metastatic thyroid cancer.

Measuring tumor growth and the effects that anticancer treatment has on growth rates is a well-known measure of the efficacy of the treatment.\(^2\)\(^5\)\(^,\)\(^7\)\(^1\)\(^2\) Here, we show that while analytical functions are useful to model single tumors, this is not the case when dealing with a population of tumors that have or have not received a particular anti-cancer treatment when the response to treatment is highly variable. Individual tumors have disparate growth rates that preclude averaging within a treatment modality because averaging presumes homogeneity of growth rate. We have shown that a statistic and stochastic approach must be used when comparing the effect of an anti-cancer therapy on a cohort of tumors. The growth rate difference is not due to the initial conditions but rather is an intrinsic characteristic of the tumor. This may be due to substantial genetic or epigenetic differences within the cancer stem cells that give rise to the tumor as well as tumor recipient variability\(^3\)\(^3\) and other variable factors regarding delivery or clearing of the therapeutic moiety from the tumor and animal. CD44$^+$ prostate cancer cells have been shown to have the stem-like properties of increased tumorigenic, clonogenic and metastatic potential.\(^3\)\(^4\) However, it was demonstrated previously that the CD44$^+$ prostate cells were a heterogeneous population containing both primitive stem cells as well as later progenitor cells.\(^3\)\(^4\) Hurt et al.\(^3\)\(^5\) later identified a rare subpopulation of CD44$^+$ CD24$^-$ prostate cancer cells with stem-like characteristics such as increased clonogenic and tumorigenic properties, and the ability to grow as non-adherent spheres in serum-replacement medium. However, this subpopulation of cells represent only 0.04% of the total LnCaP cells in culture and, tumors from mice injected with CD44$^+$ CD24$^-$ cells phenotypically resembled tumors removed from mice injected with total LnCaP cells. This indicates that CD44$^+$ CD24$^-$ cells can give rise to the heterogeneous population present in tumors derived from the LnCaP cell line. Thus, tumor heterogeneity is an intrinsic property probably dictated by the nature of the stem cell population of the tumor. Contrary to a previous report,\(^3\)\(^6\) we have found that the initial conditions (for example, tumor volume at time 0) is not a factor influencing the outcome of the treatment in our model. In fact, in the current studies, the tumor volumes at time 0 were not significantly different, yet the rates of tumor growth varied highly within a particular treatment modality group, also including the control group that received no therapy at all. Nonetheless, the results show that virotherapy treatment shifted the distribution of tumors from fast growing towards more slowly growing tumors. This shift was enhanced by radiovirotherapy. Shifting the growth rate to slower growing tumors resulted in an increase in the survival time as indicated by the strong correlation between survival probability and rate of tumor growth. It is interesting to note that these studies underscore the variable response to treatment of cancer in many human models as described by RECIST guidelines\(^2\)\(^4\) despite the use of cloned cell lines in our animal-based experiments. Thus, the tumor response to anti-cancer treatments appears as a stochastic response not deterministic. The fact that both in vitro and in vivo proliferating cancer cells divide asymmetrically to produce progeny cells with different proliferating rates may explain that the rates of tumor growth are not homogeneous in the untreated control tumor as well as the stochastic nature of treatment outcome.\(^3\)\(^7\)

In conclusion, we show here that radiovirotherapy improves therapeutic value over virotherapy alone by slowing the rate of tumor growth and improving survival time. We also show that the
radiiodine doses needed to achieve this increase scaled well within the current doses used for treatment of thyroid cancer in humans.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGEMENTS**

We thank Tracy Deckleaver at the Nuclear Medicine Animal Imaging Resource Mayo Clinic, Rochester for technical help and Dr David Dingli at the Department of Molecular Medicine, Mayo Clinic, Rochester, MN, for helpful discussion. This work was supported by Prostate SPORE Grant P50 CA 091956, Donald J Tindall, PI, John C Morris, Project Director.

**REFERENCES**

1. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. *Endocr Rev* 1999; **20**: 22–45.
2. Chiocca EA, Broadus WC, Gillies GT, Visted T, Lamfers ML. Neurosurgical delivery of chemotherapeutics, targeted toxins, and viral therapies in neuro-oncology. *J Neurooncol* 2004; **69**: 101–117.
3. McCormick F. Cancer gene therapy: fringe or cutting edge? *Nat Rev Cancer* 2001; **1**: 130–141.
4. Yamamoto M, Curiel DT. Cancer gene therapy. *Technol Cancer Res Treat* 2005; **4**: 315–330.
5. Carasco N. Iodide transport in the thyroid gland. *Biochim Biophys Acta* 1993; **1154**: 65–82.
6. Ji X, Zhao D, Zou J, Wang L, Jia X, Yu X, et al. A novel human sodium iodide symporter (NIS) promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter. *Gene Ther* 2009; **16**: 1094–1100.
7. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. *Endocr Rev* 1998; **19**: 441–456.
8. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. *Thyroid* 2002; **12**: 121–134.
9. USFDA. *Guidance for Industry: Estimating the Maximum Safe Starting Dose in Adult Healthy Volunteer. US Food and Drug Administration: Rockville, MD, 2005.*
10. Gussoni H. How to calculate the dose of chemotherapy. *Br J Cancer* 2002; **86**: 1297–1302.
11. Kozsuzko F, Bourdeau M, Bajzer Z, Dingli D. A microenvironment based model of antimitic therapy of Gompertzian tumor growth. *Bull Math Biol* 2007; **69**: 1691–1708.
12. Bajzer Z, Carr T, Jasic K, Russell SJ, Dingli D. Modeling of cancer virotherapy with recombinant measles viruses. *J Theor Biol* 2008; **252**: 109–122.
13. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. *Science* 2009; **324**: 1670–1673.
14. Patrawala L, Calhoun T, Schneider-Boussard R, Li H, Hતhata B, Tang S et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. *Oncogene* 2006; **25**: 1696–1708.
15. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. *Br J Cancer* 2008; **98**: 756–765.
16. Rennmellanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli D. Dynamics of melanoma tumor therapy with vesicular stomatitis virus: exploring the variabiliy in outcomes using mathematical modeling. *Gene Ther* 2012; **19**: 543–549.
17. Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. *Gene Therapy* 2010; **17**(11): 1325–1332.
18. Dingli D, Peng KW, Harvey ME, Greipp PR, O’Connor MK, Cattaneo R et al. Image-guided radiotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. *Blood* 2004; **103**: 1641–1646.
19. Du Bois EF. *Basal Metabolism in Health and Disease. Lea and Febiger: Philadelphia, PA, USA, 1936.*
20. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. *Br J Pharmacol* 2009; **157**: 907–921.
21. West LJ, Pierse CM, Thomas WD. Lysergic acid diethylamide: its effects on a male asialic elephant. *Science* 1962; **138**: 1100–1103.
22. Anonymous. A compound in red wine makes mice live longer, healthier. *Mayo Clinic Health Lett* 2007; **25**: 4.
23. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A et al. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 2006; **444**: 337–342.
24. Theasise P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response in treatment to solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000; **92**: 205–216.
25. Dingli D, Cascino MD, Jasic K, Russell SJ, Bajzer Z. Mathematical modeling of cancer radiovirotherapy, *Math Biosci* 2006; **199**: 55–78.
26. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. *Faseb J* 2008; **22**: 659–661.
27. Siddiqui F, Barton KN, Stricker HJ, Steyn PF, Larue SM, Karvelis KC et al. Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials. *Hum Gene Ther* 2007; **18**: 1022–1033; **19**(4): 312–322.
28. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. *Thyroid* 2002; **12**: 121–134.
29. USFDA. *Guidance for Industry: Estimating the Maximum Safe Starting Dose in Adult Healthy Volunteer. US Food and Drug Administration: Rockville, MD, 2005.*
30. Gurney H. How to calculate the dose of chemotherapy. *Br J Cancer* 2002; **86**: 1297–1302.
31. Kozusko F, Bourdeau M, Bajzer Z, Dingli D. A microenvironment based model of antimitic therapy of Gompertzian tumor growth. *Bull Math Biol* 2007; **69**: 1691–1708.
32. Bajzer Z, Carr T, Jasic K, Russell SJ, Dingli D. Modeling of cancer virotherapy with recombinant measles viruses. *J Theor Biol* 2008; **252**: 109–122.
33. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. *Science* 2009; **324**: 1670–1673.
34. Patrawala L, Calhoun T, Schneider-Boussard R, Li H, Bhatia B, Tang S et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. *Oncogene* 2006; **25**: 1696–1708.
35. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. *Br J Cancer* 2008; **98**: 756–765.
36. Rennmellanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli D. Dynamics of melanoma tumor therapy with vesicular stomatitis virus: exploring the variability in outcomes using mathematical modeling. *Gene Ther* 2012; **19**: 543–549.
37. Dey-Guha I, Wolfer A, Yeh AC, Albeck JG, Darp R, Leon E et al. Asymmetric cancer cell division regulated by AKT. *Proc Natl Acad Sci USA* 2011; **90**: 3539–3543; **108**(31): 12845–12850.